Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'

Alimentary Pharmacology and Therapeutics

Volumn 18, Issue 8, 2003, Pages 815-820

  Perri, F ^a   Festa, V ^b   Merla, A ^a   Barberani, F ^b   Pilotto, A ^a   Andriulli, A ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b SAN CAMILLO DE LELLIS HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BISMUTH CITRATE; LEVOFLOXACIN; METRONIDAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE BISMUTH CITRATE; TETRACYCLINE; TINIDAZOLE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; ERADICATION THERAPY; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL INFECTION; GLOSSITIS; HEADACHE; HELICOBACTER PYLORI; HUMAN; MAASTRICHT TRIPLE THERAPY; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SECOND LINE THERAPY; TASTE DISORDER; TREATMENT FAILURE; UREA BREATH TEST; VERTIGO; VOMITING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; AMOXICILLIN; ANTI-INFECTIVE AGENTS; ANTI-ULCER AGENTS; BENZIMIDAZOLES; BISMUTH; BREATH TESTS; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; OFLOXACIN; OMEPRAZOLE; PROSPECTIVE STUDIES; RANITIDINE; SULFOXIDES; TINIDAZOLE; TREATMENT FAILURE; UREA;

EID: 0142187289     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01755.x     Document Type: Article

References (37)

1. Malfertheiner P, Megraud F, O'Morain C, et al. The European Helicobacter pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection. The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-80.
2. Perri F, Villani R, Quitadamo M, Annese V, Niro GA, Andriulli A. Ranitidine bismuth citrate-based therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to quadruple therapy? Aliment Pharmacol Ther 2001; 15: 1017-22.
3. Wong WM, Gu Q, Lam SK, et al. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 2003; 17: 553-60.
4. Cammarota G, Cianci R, Cannizzaro O.,et al. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 1339-43.
5. Di Caro S, Zocco AM, Cremonini F, et al. Levofloxacin based regimens for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 2002; 14: 1309-12.
6. Zullo A, Hassan C, De Francesco V, et al. A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication. Dig Liver Dis 2003; 35: 232-6.
7. de Boer WA, Thys JC, Borody TJ, et al. Proposal for use of a standard side effect scoring system in studies exploring Helicobacter pylori treatment regimens. Eur J Gastroenterol Hepatol 1996; 8: 641-3.
8. 13C-urea breath test for the diagnosis of Helicobacter pylori infection. Gut 1997; 40: 459-62.
9. Perri F, Villani MR, Festa V, Quitadamo M, Andriulli A. Predictors of failure of Helicobacter pylori eradication after the standard 'Maastricht triple therapy'. Aliment Pharmacol Ther 2001; 15: 1023-9.
10. Graham DY, Lew GM, Malaty HM, et al. Factors influencing the eradication of H. pylori with triple therapy. Gastroenterology 1992; 102: 493-6.
11. Cutler AF, Schubert TT. Patient factors affecting H. pylori eradication with triple therapy. Am J Gastroenterol 1993; 88: 505-9.
12. Labenz J, Leverkus F, Borsch G. Omeprazole plus amoxycillin for cure of Helicobacter pylori infection: factors influencing the treatment success. Scand J Gastroenterol 1994; 29: 1070-5.
13. Moayyedi P, Chalmers DM, Axon AT. Patient factors that predict failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori. J Gastroenterol 1997; 32: 24-7.
14. Georgopoulos SD, Ladas SD, Karatapanis S, et al. Factors that may affect treatment outcome of triple Helicobacter pylori eradication therapy with omeprazole, amoxycillin, and clarithromycin. Dig Dis Sci 2000; 45: 63-7.
15. Russo F, Berloco P, Cuomo R, et al. Helicobacter pylori strains and histologically related lesions affect the outcome of triple eradication therapy: a study from southern Italy. Aliment Pharmacol Ther 2003; 17: 421-8.
16. Broutet N, Tchamgoue S, Pereira E, Lamouliatte H, Salamon R, Megraud F. Risk factors for failure of Helicobacter pylori therapy. Results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther 2003; 17: 99-109.
17. Perri F, Villani MR, Festa V, Quitadamo M, Andriulli A. Predictors of failure of Helicobacter pylori eradication after the standard 'Maastricht triple therapy'. Aliment Pharmacol Ther 2001; 15: 1023-9.
18. Bigard MA, Delchier JC, Riachi G, Thibault P, Barthelemy P. One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin. Aliment Pharmacol Ther 1998; 12: 383-8.
19. Deltenre M, Jonas C, Van Gossum M, Buser M, Otero J, De Koster E. Omeprazole-based antimicrobial therapies: results in 198 Helicobacter pylori-positive patients. Eur J Gastroenterol Hepatol 1997; 7(Suppl. 1): S39-44.
20. Kashimura H, Suzuki K, Hassan M, et al. Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. Aliment Pharmacol Ther 1999; 13: 483-7.
21. Wong BCY, Chang FY, Abid S, et al. Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. Aliment Pharmacol Ther 2000; 14: 1529-35.
22. Lee JM, Breslin NP, Hyde DK, Buckley MJ, O'Morain CA. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. Aliment Pharmacol Ther 1999; 13: 489-96.
23. Eclissato C, Marchioretto MA, Mendonca S, et al. Increased primary resistance to recommended antibiotics negatively affects Helicobacter pylori eradication. Helicobacter 2002; 7: 53-9.
24. Perri F, Festa V, Clemente R, Quitadamo M, Andriulli A. Rifabutin based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther 2000; 14: 311-6.
25. Gisbert JP, Pajares JM. Review article: Helicobacter pylori 'rescue' regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002; 16: 1047-57.
26. Pilotto A, Franceschi M, Rassu M, Furlan F, Scagnelli M. In vitro activity of rifabutin against strains of Helicobacter pylori resistant to metronidazole and clarithromycin. Am J Gastroenterol 2000; 95: 833-4.
27. Perri F, Festa V, Andriulli A. Treatment of antibiotic-resistant Helicobacter pylori. N Engl J Med 1998; 339: 53.
28. Bock H, Koop H, Lehn N, Heep M. Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience. J Clin Gastroenterol 2000; 31: 222-5.
29. Perri F, Festa V, Clemente R, et al. Randomised study of two 'rescue' therapies for Helicobacter pylori infected patients after failure of standard triple therapies. Am J Gastroenterol 2001; 96: 58-62.
30. Canducci F, Ojetti V, Pola P, Gasbarrini G, Gasbarrini A. Rifabutin-based Helicobacter pylori eradication 'rescue therapy'. Aliment Pharmacol Ther 2001; 15: 143.
31. Gisbert JP, Calvet X, Bujanda L, Marcos S, Gisbert JL, Pajares JM. 'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter 2003; 8: 90-4.
32. Heep M, Lehn N, Brandstatter B, Rieger U, Senzenberger S, Wehrl W. Detection of rifabutin resistance and association of rpoB mutations with resistance to four rifamycin derivatives in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2002; 21: 143-5.
33. Pilotto A, Franceschi M, Rassu M, et al. Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study. Dig Liver Dis 2000; 32: 667-72.
34. Segura AM, Gutierrez O, Otero W, Angel A, Genta RM, Graham DY. Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1997; 11: 529-32.
35. Katelaris PH, Forbes GM, Talley NJ, Crotty B. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: the QUADRATE Study. Gastroenterology 2002; 123: 1763-9.
36. Williams MP, Pounder RE. Review article: the pharmacology of rabeprazole. Aliment Pharmacol Ther 1999; 13(Suppl. 3): 3-10.
37. Stedman CA, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000; 14: 963-78.